BofA raises Bristol-Myers Squibb stock price target to $67
BofA Securities increased its price target for Bristol-Myers Squibb (BMY) to $67 from $66, citing a 3% revenue beat and raised 2026 sales guidance. The company's stock trades at a P/E ratio of 13.4. Analysts have mixed views on the company's future prospects, with some citing potential upside from key programs and others expressing concerns over exclusivity events and drug data.
How this was made
The 30-second read
Why it matters
Analyst target upgrades can trigger short‑term buying pressure, especially when tied to fresh earnings beats.
Market read
The price‑target raise provides a fresh catalyst for BMY, likely generating modest buying interest.
What to watch
Potential headwinds from Eliquis exclusivity loss in Europe and mixed trial data for new programs could temper upside.
Background
BofA's target increase follows Bristol‑Myers Squibb's Q3 results that beat expectations and prompted a full‑year revenue guidance lift.
Ticker impact
BofA Securities raised its price target on Bristol-Myers Squibb to $67, citing a revenue beat and higher FY2026 guidance.
likely upward pressure as investors price in the higher target and earnings beat
The target raise follows a fresh earnings beat and guidance lift, providing a concrete catalyst for short‑term buying.
Market effects
May boost sentiment in the broader pharma sector as peers are seen to benefit from strong earnings trends.
Limited to U.S. markets where BMY is listed; no broader regional effect.
Minor global impact, primarily affecting investors tracking large-cap US pharma stocks.
Counterpoint
The target raise is modest and may already be priced in; downside risk remains from upcoming loss‑of‑exclusivity events.
Key entities
- companyBristol‑Myers Squibb
Large‑cap pharmaceutical company (ticker BMY).
- analystBofA Securities
Investment bank raising the price target.
